Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2021, 30(3):159-167

Necroptosis-mediated damage of atrial myocardium - another proarrhythmic factor of atrial fibrillation?

Horváth C1, Jarabicová I1, Beňa M2, Beňačka O3, Hulman M2, 4, Hlivák P3, 5, Hatala R3, 5, Duriš Adameová A1
1 Katedra farmakológie a toxikológie, Farmaceutická fakulta Univerzita Komenského v Bratislave, Bratislava
2 Oddelenia kardiochirurgie, NÚSCH, a. s., Bratislava
3 Oddelenia arytmií a kardiostimulácie, NÚSCH, a. s., Bratislava
4 Kardiochirugickej klinika LFUK a NÚSCH, a. s., Bratislava
5 Klinika kardiológie a angiológie Lekárská fakulta Slovenskej zdravotníckej univerzita a NÚSCH, a. s., Bratislava, Slovenská republika

Atrial fibrillation (AF) is the most common heart rhythm disorder worldwide, with a dominant position in the epidemiology of cardiovascular diseases. In spite of a number of various therapeutic approaches for the restoration and/or maintenance of sinus rhythm, the mortality of patients with AF is twice as high as in patients with sinus rhythm. This suggest that other, so far unknown, factors are likely responsible for atrial damage, and that targeting such factors might be more beneficial in the management of AF. It is known that besides electrical and contractile remodelling, structural remodelling of atria, particularly due to inflammation-related fibrosis, also plays an important role in the complex pathophysiology of AF. Inflammatory response is also closely associated with recently discovered necroptotic cell death, which is defined as a RIP3-MLKL-driven cell death modality with a necrosis-like phenotype. It has been shown that necroptosis is implemented in the pathogenesis of ischemic heart disease as well as heart failure. In this study, we present a hypothesis about a plausible role of necroptosis in the atrial damage and its linkage with inflammation which may result in AF. The individual premises of our hypothesis are based on the results of a pilot study and on the basis of them we indicate future direction of research in this field of cardiology.

Keywords: atrial fibrillation; necroptosis; inflammation

Published: March 1, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horváth C, Jarabicová I, Beňa M, Beňačka O, Hulman M, Hlivák P, et al.. Necroptosis-mediated damage of atrial myocardium - another proarrhythmic factor of atrial fibrillation? Cardiology Letters. 2021;30(3-4):159-167.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Andrade J, Khairy P, Dobrev D, et al. The clinical profile and pathophysiology of atrial fibrillation: Relationships among clinical features, epidemiology, and mechanisms. Circ Res 2014;114:1453-1468. doi:10.1161/CIRCRESAHA.114.303211. Go to original source...
    2. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-2962. doi:10.1093/eurheartj/ehw210. Go to original source...
    3. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for CardioThoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the Europea. Eur Heart J 2021;42:373-498. doi:10.1093/eurheartj/ehaa612. Go to original source...
    4. Heeringa J, Van Der Kuip DAM, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study. Eur Heart J 2006;27:949-953. doi:10.1093/eurheartj/ehi825. Go to original source...
    5. Schotten U, Verheule S, Kirchhof P, et al. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev 2011;91:265-325. doi:10.1152/physrev.00031.2009. Go to original source...
    6. Svennberg E, Engdahl J, Al-Khalili F, et al. Mass screening for untreated atrial fibrillation: the STROKESTOP Study. Circulation 2015;131:2176-2184. doi:10.1161/CIRCULATIONAHA.114.014343. Go to original source...
    7. Lau DH, Schotten U, Mahajan R, et al. Novel mechanisms in the pathogenesis of atrial fibrillation: Practical applications. Eur Heart J 2016;37:1573-1581. doi:10.1093/eurheartj/ehv375. Go to original source...
    8. Fatkin D, Santiago CF, Huttner IG, et al. Genetics of atrial fibrillation: State of the Art in 2017. Hear Lung Circ 2017;26:894-901. doi:10.1016/j.hlc.2017.04.008. Go to original source...
    9. Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation. Eur Heart J 2010;31:2369-2429. doi:10.1093/eurheartj/ehq278. Go to original source...
    10. Todorov H, Janssen I, Honndorf S, et al. Clinical significance and risk factors for new onset and recurring atrial fibrillation foll­ owing cardiac surgery - a retrospective data analysis. BMC Anesthesiol 2017;17:163. doi:10.1186/s12871-017-0455-7. Go to original source...
    11. Rezaei Y, Peighambari MM, Naghshbandi S, et al. Postoperative atrial fibrillation following cardiac surgery: from pathogenesis to potential therapies. Am J Cardiovasc Drugs. 2020;20:19-49. doi:10.1007/s40256-019-00365-1. Go to original source...
    12. Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol 2014;63:2335-2345. doi:https://doi.org/10.1016/j.jacc.2014.02.555. Go to original source...
    13. Denham NC, Pearman CM, Caldwell JL, et al. Calcium in the pathophysiology of atrial fibrillation and heart failure. Front Physiol 2018;9:1380. Go to original source...
    14. Voigt N, Heijman J, Wang Q, et al. Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation. Circulation 2014;129:145-156. doi:10.1161/CIRCULATIONAHA.113.006641. Go to original source...
    15. Platonov PG. Atrial fibrosis: An obligatory component of arrhythmia mechanisms in atrial fibrillation? J Geriatr Cardiol 2017;14:233-237. doi:10.11909/j.issn.1671-5411.2017.04.008.
    16. Karam BS, Chavez-Moreno A, Koh W, et al. Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes. Cardiovasc Diabetol 2017;16:17-20. doi:10.1186/s12933-017-0604-9. Go to original source...
    17. Reilly SN, Jayaram R, Nahar K, et al. Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: Implications for the antiarrhythmic effect of statins. Circulation 2011;124:1107-1117. doi:10.1161/CIRCULATIONAHA.111.029223. Go to original source...
    18. Youn J-Y, Zhang J, Zhang Y, et al. Oxidative stress in atrial fibrillation: an emerging role of NADPH oxidase. J Mol Cell Cardiol 2013;62:72-79. doi:10.1016/j.yjmcc.2013.04.019. Go to original source...
    19. Erbo Y, Lu W-H, He P, et al. TGF-β1 signal pathway in the regulation of inflammation in patients with atrial fibrillation. Asian Pac J Trop Med 2013;6:999-1003. doi:10.1016/S19957645(13)60180-7. Go to original source...
    20. Babapoor-Farrokhran S, Tarighati Rasekhi R, Gill D, et al. How transforming growth factor contributes to atrial fibrillation? Life Sci 2021;266:118823. doi:10.1016/j.lfs.2020.118823. Go to original source...
    21. Purohit A, Rokita AG, Guan X, et al. Oxidized Ca2+/Calmodulin-dependent protein kinase II triggers atrial fibrillation. Circulation 2013;128:1748-1757. doi:10.1161/CIRCULATIONAHA.113.003313. Go to original source...
    22. Liu Z, Finet JE, Wolfram JA, et al. Calcium/calmodulin-dependent protein kinase II causes atrial structural remodeling associated with atrial fibrillation and heart failure. Hear Rhythm 2019;16:1080-1088. doi:10.1016/j.hrthm.2019.01.013. Go to original source...
    23. Sethi R, Adameova A, Dhalla KS, et al. Modification of Epinephrine-induced arrhythmias by N-Acetyl-L-Cysteine and vitamin E. J Cardiovasc Pharmacol Ther 2009;14:134-142. doi:10.1177/1074248409333855. Go to original source...
    24. Adameova A, Shah AK, Dhalla NS. Role of oxidative stress in the genesis of ventricular arrhythmias. Int J Mol Sci 2020;21:1-16. doi:10.3390/ijms21124200. Go to original source...
    25. Gasparova I, Kubatka P, Opatrilova R, et al. Perspectives and challenges of antioxidant therapy for atrial fibrillation. Naunyn Schmiedebergs Arch Pharmacol 2017;390:1-14. doi:10.1007/s00210-016-1320-9. Go to original source...
    26. Samman Tahhan A, Sandesara PB, Hayek SS, et al. Association between oxidative stress and atrial fibrillation. Heart Rhythm 2017;14:1849-1855. doi:10.1016/j.hrthm.2017.07.028. Go to original source...
    27. Baek Y-S, Kim T-H, Uhm J-S, et al. Prevalence and the clinical outcome of atrial fibrillation in patients with autoimmune rheumatic disease. Int J Cardiol 2016;214:4-9. doi:10.1016/j.ijcard.2016.03.083. Go to original source...
    28. Gungor B, Ekmekci A, Arman A, et al. Assessment of interleukin-1 gene cluster polymorphisms in lone atrial fibrillation: new insight into the role of inflammation in atrial fibrillation. Pacing Clin Electrophysiol 2013;36:1220-1227. doi:10.1111/pace.12182. Go to original source...
    29. Luan Y, Guo Y, Li S, et al. Interleukin-18 among atrial fibrillation patients in the absence of structural heart disease. Eur Pacing, Arrhythmias, Card Electrophysiol J Work Groups Card Pacing, Arrhythmias, Card Cell Electrophysiol. Eur Soc Cardiol 2010;12:1713-1718. doi:10.1093/europace/euq321. Go to original source...
    30. Yao C, Veleva T, Scott L, et al. Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation. Circulation 2018. doi:10.1161/CIRCULATIONAHA118.035202 Go to original source...
    31. Franchi L, Eigenbrod T, Muñoz-Planillo R, et al. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 2009;10:241247. doi:10.1038/ni.1703. Go to original source...
    32. Lawlor KE, Khan N, Mildenhall A, et al. RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL. Nat Commun 2015;6:6282. doi:10.1038/ncomms7282. Go to original source...
    33. Grootjans S, Vanden Berghe T, Vandenabeele P. Initiation and execution mechanisms of necroptosis: an overview. Cell Death Differ 2017;24:1184-1195. doi:10.1038/cdd.2017.65. Go to original source...
    34. Wu X-N, Yang Z-H, Wang X-K, et al. Distinct roles of RIP1RIP3 hetero- and RIP3-RIP3 homo-interaction in mediating necroptosis. Cell Death Differ 2014;21:1709-1720. doi:10.1038/cdd.2014.77. Go to original source...
    35. Zhao J, Jitkaew S, Cai Z, et al. Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proc Natl Acad Sci U S A 2012;109:5322-5327. doi:10.1073/pnas.1200012109. Go to original source...
    36. Wang H, Sun L, Su L, et al. Mixed lineage kinase domainlike protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol Cell 2014;54:133-146. doi:10.1016/j.molcel.2014.03.003. Go to original source...
    37. Czabotar PE, Murphy JM. A tale of two domains - a structural perspective of the pseudokinase, MLKL. FEBS J 2015;282:42684278. doi:https://doi.org/10.1111/febs.13504. Go to original source...
    38. Xia B, Fang S, Chen X, et al. MLKL forms cation channels. Cell Res 2016;26:517-528. doi:10.1038/cr.2016.26. Go to original source...
    39. Degterev A, Huang Z, Boyce M, et al. Chemical inhibitor of non­ apoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005;1:112. Go to original source...
    40. Adameova A, Hrdlicka J, Szobi A, et al. Evidence of necroptosis in hearts subjected to various forms of ischemic insults. Canadian Journal of Physiology and Pharmacology 2017:1-29. doi:10.1139/cjpp-2016-0609. Go to original source...
    41. Szobi A, Farkašová-Ledvényiová V, Lichý M, et al. Cardioprotection of ischaemic preconditioning is associated with inhibition of translocation of MLKL within the plasma membrane. J Cell Mol Med 2018;22:4183-4196. doi:10.1111/jcmm.13697. Go to original source...
    42. Szobi A, Gonçalvesová E, Varga ZV, et al. Analysis of necroptotic proteins in failing human hearts. J Transl Med 2017;15:86. doi:10.1186/s12967-017-1189-5. Go to original source...
    43. Lichý M, Szobi A, Hrdlička J, et al. Different signalling in infarcted and non-infarcted areas of rat failing hearts: A role of necroptosis and inflammation. J Cell Mol Med 2019;23. doi:10.1111/jcmm.14536. Go to original source...
    44. Corsetti G, Chen-Scarabelli C, Romano C, et al. Autophagy and oncosis/necroptosis are enhanced in cardiomyocytes from heart failure patients. Med Sci Monit Basic Res 2019;25:33-44. doi:10.12659/MSMBR.913436. Go to original source...
    45. Zhou W, Yuan J. Necroptosis in health and diseases. Semin Cell Dev Biol 2014;35:14-23. doi:https://doi.org/10.1016/j.semcdb.2014.07.013. Go to original source...
    46. Stolberg-Stolberg J, Sambale M, Hansen U, et al. Cartilage trauma induces necroptotic chondrocyte death and expulsion of cellular contents. Int J Mol Sci 2020;21:4204. doi:10.3390/ijms21124204. Go to original source...
    47. Adameova A, Goncalvesova E, Szobi A, et al. Necroptotic cell death in failing heart: relevance and proposed mechanisms. Heart Fail Rev 2016;21:213-221. doi:10.1007/s10741-016-9537-8. Go to original source...
    48. Hu X-M, Chen X, Pang H-Y, et al. Plasma levels of receptor interacting protein kinase-3 correlated with coronary artery disease. Chin Med J (Engl) 2019;132:1400-1405. doi:10.1097/CM9.0000000000000225. Go to original source...
    49. Hu X, Li H, Chen X, et al. Plasma concentration of receptor-interacting protein kinase-3 as a potential biomarker for diagnosis and prognosis in heart failure. Clin Chim Acta 2020;509:273279. doi:https://doi.org/10.1016/j.cca.2020.06.039. Go to original source...
    50. Smith CCT, Davidson SM, Lim SY, et al. Necrostatin: A potentially novel cardioprotective agent? Cardiovasc Drugs Ther 2007;21:227-233. doi:10.1007/s10557-007-6035-1. Go to original source...
    51. Koshinuma S, Miyamae M, Kaneda K, et al. Combination of necroptosis and apoptosis inhibition enhances cardioprotection against myocardial ischemia-reperfusion injury. J Anesth 2014;28:235-241. doi:10.1007/s00540-013-1716-3. Go to original source...
    52. Koudstaal S, Oerlemans MIFJ, Van der Spoel TIG, et al. Necrostatin-1 alleviates reperfusion injury following acute myocardial infarction in pigs. Eur J Clin Invest 2015;45:150-159. doi:10.1111/eci.12391. Go to original source...
    53. Dmitriev YV, Minasian SM, Demchenko EA, et al. Study of cardioprotective effects of necroptosis inhibitors on isolated rat heart subjected to global ischemia-reperfusion. Bull Exp Biol Med 2013;155:245-248. doi:10.1007/s10517-013-2124-2. Go to original source...
    54. Zhang T, Zhang Y, Cui M, et al. CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress - induced myocardial necroptosis. Nat Med 2016. doi:10.1038/nm.4017. Go to original source...
    55. Lim SY, Davidson SM, Mocanu MM, et al. The cardioprotective effect of necrostatin requires the cyclophilin-D component of the mitochondrial permeability transition pore. Cardiovasc Drugs Ther 2007;21:467-9. doi:10.1007/s10557-007-6067-6. Go to original source...
    56. Ren M, Li X, Hao L, et al. Role of tumor necrosis factor alpha in the pathogenesis of atrial fibrillation: A novel potential therapeutic target? Ann Med 2015;47:316-324. doi:10.3109/07853890.2015.1042030. Go to original source...
    57. Oberst A, Dillon CP, Weinlich R, et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 2011;471:363-367. doi:10.1038/nature09852. Go to original source...
    58. Han W, Fu S, Wei N, et al. Nitric oxide overproduction derived from inducible nitric oxide synthase increases cardiomyocyte apoptosis in human atrial fibrillation. Int J Cardiol 2008;130:165-173. doi:10.1016/j.ijcard.2008.02.026. Go to original source...
    59. Zhao J, Li J, Li W, et al. Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing. Br J Pharmacol 2010;159:1584-1594. doi:10.1111/j.1476-5381.2009.00551.x. Go to original source...
    60. Heger J, Warga B, Meyering B, et al. TGFβ receptor activation enhances cardiac apoptosis via SMAD activation and concomitant NO release. J Cell Physiol 2011;226:2683-2690. doi:10.1002/jcp.22619. Go to original source...
    61. Dzeshka MS, Lip GYH, Snezhitskiy V, et al. Cardiac fibrosis in patients with atrial fibrillation: mechanisms and clinical implications. J Am Coll Cardiol 2015;66:943-959. doi:10.1016/j.jacc.2015.06.1313. Go to original source...
    62. Trappe K, Thomas D, Bikou O, et al. Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3: A pre-clinical pilot study. Eur Heart J 2013;34:147-157. doi:10.1093/eurheartj/ehr269. Go to original source...

    Return to the content